AlphaYou
Overview
Smart money at a glance
Filings to Oct 11, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 0 cutMore adding
Market overview
Fundamentals Jul 14- 52-wk high
- $4.18
- 52-wk low
- $1.10
- Mkt cap
- $819.5M
- Fwd P/E
- 4.6x
- Beta
- 1.06
- P/S
- 2.0x
- P/B
- 98.4x
- Profit margin
- -1.8%
- Op margin
- -8.2%
- ROE
- -260.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ESPR filings
Are insiders buying or selling Esperion Therapeutics Inc (ESPR) stock?
Neither. Esperion Therapeutics Inc (ESPR) insiders filed no open-market purchases or sales in the 90 days to Oct 11, 2026, according to SEC Form 4 filings.
Which members of Congress have traded ESPR recently?
None. No member of Congress disclosed a ESPR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this ESPR smart-money data?
This summary uses filings available on Oct 11, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- TS
Two Sigma
$8.4M
added
- FM
FMR LLC
$13.6M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in ESPR right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in $0.10 a share below what analysts expected.
Last report
May 8, 2026
Period ending
Mar 31, 2026
Earnings per share
-$0.00 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Mar 31, 2026 | May 8, 2026 | -$0.10 / -$0.00Alpha Vantage | -$0.10 miss | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 10, 2026 | $0.22 / $0.29Alpha Vantage | -24.55% miss | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | -$0.16 / $0.02Alpha Vantage | -$0.18 miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | -$0.06 / -$0.14Alpha Vantage | +57.14% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 6, 2025 | -$0.21 / -$0.15Alpha Vantage | -37.53% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 4, 2025 | -$0.10 / -$0.16Alpha Vantage | +35.68% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 7, 2024 | -$0.15 / -$0.18Alpha Vantage | +16.67% beat | Unavailable | Unavailable |
| Jun 30, 2024 | Aug 12, 2024 | -$0.33 / -$0.18Alpha Vantage | -83.33% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
What the street expects next
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -1.8%
- P/E
- 0.00
- Forward P/E
- 4.64
- Market cap
- $819M
Valuation
- P/S1.96
- P/B98.42
- Dividend yield0.0%
Quality
- Operating margin-8.2%
- ROE-260.8%
- ROA12.0%
Growth
- Beta1.06
Technicals
Price structure
Market data unavailable.